Idev Technologies Incorporated
WEBSTER, Texas, December 15, 2011 -
IDEV Technologies, Inc.
WEBSTER, Texas, November 10, 2011 -
Lower Profile Provides Easier Operation, Improved Delivery Control and Efficiencies
IDEV Technologies, Incorporated (IDEV), today announced the FDA has granted 510(k) clearance for the company's 6 French (6Fr) SUPERA VERITAS Transhepatic Biliary Stent System.
WEBSTER, Texas, July 12, 2011 -
- Improved Operation and Control Make Stent Delivery More
Efficient and Predictable
IDEV Technologies, Incorporated (IDEV), today announced the
first procedures in Europe utilizing the new 6 French (6Fr) SUPERA
VERITAS Peripheral Vascular System.
WEBSTER, Texas, June 2, 2011 -
- IDE Study Examines Performance of SUPERA(R) Stent in Superficial
Femoral Artery (SFA)
IDEV Technologies, Inc.
NOORDWIJKERHOUT, Netherlands and WEBSTER, Texas, May 17, 2011 - IDEV Technologies announced today that data from a long lesion study of
182 patients with significantly diseased superficial femoral arteries and
popliteal arteries showed high patency rates and no stent fractures after
treatment with the SUPERA VERITAS(R) Peripheral Vascular Stent System.
More News
- IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITAS(R)
- Zero Fractures and Impressive Patency Results Reported for Unique Stent from IDEV Technologies
- Impressive Two-Year Patency Results Reported for SFA Procedures, with Zero Stent Fractures
- Commercial Launch of Stent Delivery System Planned for Early 2011
- New SUPERA(R) Delivery System Improves Procedure Predictability and Stent Performance
- New Sizes of SUPERA(R) Stent Expand Treatment Options for Peripheral Vascular Disease
- Proceeds to Fund Clinical Trials, New Product Development, Continued Revenue Growth
- Company Expands Product Portfolio
- Provides Significant and Broad Expertise in Clinical Trials, Regulatory Affairs
- Innovative Technology Provides Precision, Ease of Use For Delivery of SUPERA(R) Stent
